

## Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) manufactured by Pharmascience Inc., Salazopyrin 500 mg Tablet (DIN 02064480) manufactured by Pfizer Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of May 1, 2016, all claims for Salazopyrin 500 mg Tablet (DIN 02064480) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Apotex Inc. that the shortages of pms-Lithium Carbonate 300 mg Capsule (DIN 02216140) and Apo-Lithium Carbonate 300 mg Capsule (DIN 02242838) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 6, 2016**.

### LITHIUM CARBONATE

#### 300 MG CAPSULE

00002216140	PMS-LITHIUM CARBONATE	PMS	\$0.0443
00002242838	APO-LITHIUM CARBONATE	APX	\$0.0657
00000236683	CARBOLITH	VCL	\$0.0964

... continued from previous page

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC and Pharmascience Inc. that the shortages of Mylan-Risperidone ODT 3 mg Orally Disintegrating Tablet (DIN 02413515) and pms-Risperidone ODT 3 mg Orally Disintegrating Tablet (DIN 02370697) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 6, 2016**.

## RISPERIDONE

### 3 MG DISINTEGRATING TABLET

00002413515	MYLAN-RISPERIDONE ODT	MYP	\$1.5275
00002370697	PMS-RISPERIDONE ODT	PMS	\$1.5275
00002268086	RISPERDAL M-TAB	JAI	\$3.2078

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.609 2016/05

